Article
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
JACC. Cardiovascular imaging - 1 Jul 2022
Nicholls Stephen J, Kataoka Yu, Nissen Steven E, Prati Francesco, Windecker Stephan, Puri Rishi, Hucko Thomas, Aradi Daniel, Herrman Jean-Paul R, Hermanides Renicus S, Wang Bei, Wang Huei, Butters Julie, Di Giovanni Giuseppe, Jones Stephen, Pompili Gianluca, Psaltis Peter J
Abstract excerpt
BACKGROUND: The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab produced coronary atheroma regression in statin-treated patients. OBJECTIVES: The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition. METHODS: Patients with a non-ST-segment elevation myocardial infarction were treated with monthly evolocumab 420 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
